Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	31.96B +5.5%
Revenue (ttm)	12.95B -0.1%
Net Income	2.34B +5.8%
EPS	2.61 +8.9%
Shares Out	n/a
PE Ratio	13.65
Forward PE	12.65
Dividend	1.20 (4.09%)
Ex-Dividend Date	Jun 13, 2025

Volume	790,786
Average Volume	869,427
Open	29.56
Previous Close	29.96
Day's Range	29.12 - 30.10
52-Week Range	24.85 - 41.85
Beta	0.37
RSI	45.35
Earnings Date	Mar 25, 2026

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY